Veradermics, Incorporated
NYSE:MANE · New York Stock Exchange
-$1.13 today
Vol 0.82M · Avg 0.58M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NYSE:MANE · Revenue to Net Income
No earnings data available.
Income Statement
Annual data · 3 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $888.0M | $1.0B | $809.6M |
| Cost of Revenue | $0 | $0 | $0 | -$1.7B | $344.8M | $725.6M |
| Gross Profit | $0 | $0 | $0 | $11.6B | $10.3B | $8.9B |
| Gross Margin | — | — | — | 26.4% | 45.5% | 9.8% |
| Research & Development | $62.1M +166.6% | $23.3M +55.5% | $15.0M | $1.2B | $378.4M | $983.2M |
| Selling, General & Admin | $10.3M +194.2% | $3.5M +48.5% | $2.4M | $811.0M | $1.4B | $620.6M |
| Operating Expenses | $72.3M +170.2% | $26.8M +54.6% | $17.3M | -$15.9B | $3.6B | $5.3B |
| Depreciation & Amortization | $0 | $0 | $0 | $419.0M | $1.2B | $374.2M |
| EBITDA | -$70.0M -170.2% | -$25.9M -57.4% | -$16.5M | $10.0B | $12.6B | -$15.2B |
| EBITDA Margin | — | — | — | 14.3% | 10.0% | 5.6% |
| Operating Income | -$72.3M -170.2% | -$26.8M -54.6% | -$17.3M | $9.0B | $10.6B | $12.3B |
| Operating Margin | — | — | — | 11.2% | 18.7% | 16.6% |
| Interest Income | $1.6M +224.7% | $481.0K -44.7% | $870.0K | $875.4M | $1.3B | -$1.5B |
| Interest Expense | $0 -100.0% | $585.0K +1525.0% | $36.0K | $801.2M | $969.2M | $1.1B |
| Other Income / Expenses | $2.4M +711.0% | $290.0K -65.2% | $834.0K | $368.6M | -$1.6B | -$1.5B |
| Income Before Tax | -$70.0M -164.3% | -$26.5M -60.6% | -$16.5M | $13.9B | -$15.6B | $3.3B |
| Pre-Tax Margin | — | — | — | 15.4% | 13.3% | 20.8% |
| Income Tax Expense | $0 | $0 | $0 | $375.6M | $666.8M | $1.3B |
| Net Income | -$70.0M -164.3% | -$26.5M -60.6% | -$16.5M | $5.1B | $5.0B | $4.9B |
| Net Margin | — | — | — | 47.3% | 7.4% | 12.4% |
| EPS (Basic) | -$2 -1600.0% | -$0 -70.9% | -$0 | $591.2M | $1.2B | $400.8M |
| EPS (Diluted) | -$2 -1600.0% | -$0 -70.9% | -$0 | $777.4M | $620.6M | $766.2M |
| Weighted Avg Shares | $35.1M -82.6% | $201.3M +0.0% | $201.3M | $724.2M | $892.2M | $757.8M |
| Weighted Avg Shares (Diluted) | $35.1M -82.6% | $201.3M +0.0% | $201.3M | $566.0M | $319.6M | $1.2B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Travere Therapeutics, Inc.
NASDAQ:TVTX
$5.05B
Abeona Therapeutics Inc.
NASDAQ:ABEO
$324.30M
Ovid Therapeutics Inc.
NASDAQ:OVID
$309.27M
Cybin Inc. Common Stock
NASDAQ:HELP
$225.02M
Tharimmune, Inc.
THAR
$139.94M
Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYX
$110.57M
Lisata Therapeutics, Inc.
LSTA
$32.56M
XTL Biopharmaceuticals Ltd.
XTLB
$5.69M
Adial Pharmaceuticals, Inc.
ADIL
$2.68M
Dermata Therapeutics, Inc.
DRMA
$863,260.00
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does MANE generate?
Veradermics, Incorporated (MANE) reported $0.00 of revenue in fiscal 2025.
Is MANE profitable?
Veradermics, Incorporated (MANE) reported -$69,995,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.